Form 4: Quanterix Director Myla Lai-Goldman Reports Significant Equity Holdings Post-Akoya Acquisition

Quanterix Corporation Director Myla Lai-Goldman reported the acquisition of common stock, restricted stock units, and stock options on July 8, 2025, following Quanterix's acquisition of Akoya Biosciences, Inc.

Summary

• Myla Lai-Goldman, a Director of Quanterix Corp., acquired 2,940 shares of Quanterix common stock on July 8, 2025.
• This acquisition was part of Quanterix's acquisition of Akoya Biosciences, Inc., where 20,000 shares of Akoya common stock were exchanged.
• The exchange rate for the acquisition was 0.1470 shares of Quanterix common stock and $0.37 in cash for each Akoya share.
• The closing price of Quanterix common stock on July 8, 2025, was $6.54 per share, while Akoya's closing price on July 7, 2025, was $1.29 per share.
• Additionally, Lai-Goldman acquired 24,464 restricted stock units (RSUs) on July 8, 2025, which vest one-third annually on July 8, 2026, July 8, 2027, and July 8, 2028.
• Lai-Goldman also acquired 50,758 stock options with an exercise price of $6.54 on July 8, 2025, expiring on July 8, 2035.
• These options vest one-third on July 8, 2026, with the remaining two-thirds vesting monthly over the subsequent two years.
• Following these transactions, Lai-Goldman beneficially owns 27,404 shares of common stock (including RSUs) and 50,758 stock options.

Sentiment

Score: 7

Explanation: The filing reports a director's increased equity stake in Quanterix following an acquisition, which is generally a positive signal of alignment and commitment. The acquisition itself implies strategic growth. There are no negative financial or operational details within this specific Form 4.

Positives

• Director Myla Lai-Goldman's increased equity holdings align her interests with shareholders, signaling confidence in the company's future.
• The reported transactions are a direct result of Quanterix's acquisition of Akoya Biosciences, Inc., indicating strategic growth and expansion.

Future Outlook

The vesting schedules for restricted stock units and stock options extend through July 2028 and July 2035, respectively, indicating a long-term incentive structure for the director and a commitment to the company's future performance.

Management Comments

• The undersigned hereby constitutes and appoints each of Laurie Churchill, Brian Keane, David Engvall and Bonnie McManus as the undersigned's true and lawful attorney-in-fact to execute for and on behalf of the undersigned, in the undersigned's capacity as a beneficial owner of Quanterix Corporation, Forms 3, 4, and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder and Schedules 13D and 13G in accordance with Section 13 of the Securities Exchange Act of 1934 and the rules thereunder.

Industry Context

This filing reflects the integration phase following Quanterix's acquisition of Akoya Biosciences, Inc., a common strategy in the life sciences and diagnostics industry for expanding market share and technological capabilities. Such acquisitions often involve equity-based compensation for key personnel from the acquired entity to ensure retention and alignment with the acquiring company's goals.

Comparison to Industry Standards

• The compensation structure, involving a mix of common stock, restricted stock units, and stock options, is a standard practice in the biotechnology and diagnostics sectors for executive and director compensation following mergers and acquisitions.
• The vesting schedules are typical for long-term incentive plans, aiming to retain talent and align interests over several years.
• Specific comparable companies or projects are not detailed in this filing, as it focuses on individual beneficial ownership changes rather than a comprehensive M&A report.

Corporate Governance

Stakeholder Impact

• Shareholders: Director's increased equity holdings align interests with shareholders, potentially signaling confidence in the company's future post-acquisition.
• Employees: The acquisition of Akoya Biosciences, Inc. and the subsequent equity grants to a director (potentially from the acquired entity) may impact employee morale and retention, though specific details are not provided.

Next Steps

• Vesting of 24,464 restricted stock units on July 8, 2026, July 8, 2027, and July 8, 2028.
• Vesting of 50,758 stock options, with one-third on July 8, 2026, and the remainder monthly over two years.

Key Dates

Recommendation

Keywords

Quanterix Corp, QTRX, Akoya Biosciences, Acquisition, SEC Form 4, Beneficial Ownership, Stock Options, Restricted Stock Units, Insider Transaction, Director Holdings, Equity Compensation